Astellas and Sangamo Therapeutics partner to develop gene therapies for neurological diseases.

Astellas and Sangamo Therapeutics have entered into a licensing agreement to develop genomic medicines for treating neurological diseases. The agreement focuses on using capsid technology, which is crucial for delivering gene therapies directly to the brain and nervous system. This collaboration aims to advance treatments for conditions that currently have limited therapeutic options.

December 19, 2024
5 Articles